PharmaCyte Biotech sells Femasys stake, boosts cash to $20 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
November 25, 2025 9:15 AM ESTLAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Companys strategic approach to capital deployment and strengthening its already solid financial position.
Following the monetization of the stake, PharmaCytes cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 2025. This transaction highlights the Companys ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk... More
